Welcome to our dedicated page for PRECIGEN SEC filings (Ticker: PGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Precigen, Inc. filings document the company’s biopharmaceutical operations, commercial product disclosures, governance matters, and capital structure. Form 8-K reports cover financial results, PAPZIMEOS business updates, investor presentations, commercial supply arrangements, and financing agreements tied to the company’s transition into commercial-stage operations.
Precigen’s proxy materials describe board elections, auditor ratification, executive compensation votes, and equity incentive plan matters. Other filings disclose its Nasdaq-listed common stock, preferred-stock conversion activity, senior secured debt arrangements, material agreements, risk factors, and corporate governance controls relevant to a public precision-medicine company.
PRECIGEN, INC. (PGEN) is the issuer for a Rule 144 notice filed on behalf of officer Rutul Shah. The notice covers a proposed sale of up to 34,658 shares of common stock on or after 08/21/2026, to be delivered from a stock option exercise through Fidelity Brokerage Services LLC. PRECIGEN common shares outstanding are listed as 358,035,247 as a reference figure.
PRECIGEN, INC. Chief Operating Officer Rutul R Shah completed a sale of 32,739 shares of Common Stock on 2026-08-06 at $6.86 per share in a sale classified as an open-market or private transaction under a Rule 10b5-1 trading plan, and now directly holds 465,012 shares.
Precigen, Inc. received an amended Schedule 13G filing (Amendment No. 6) from Ares Trading SA, Merck Serono SA, Merck KGaA and E. Merck KG, collectively reporting their position in Precigen’s common stock. These affiliated entities together beneficially own 17,467,152 shares of common stock.
The filing reports 4.9% of the outstanding class, with sole voting and dispositive power over all 17,467,152 shares and no shared voting or dispositive power. The 4.9% figure is calculated using 358,035,247 shares outstanding as of July 31, 2026, as reported in Precigen’s Form 10-Q. The group states that it now owns 5 percent or less of the class and has entered into a Joint Filing Agreement to report this ownership collectively.
Precigen, Inc. filed a notice relating to the sale of common stock on NASDAQ through Fidelity Brokerage Services LLC. The filing lists 32,739 common securities with an aggregate value of $224,589.54 and references total related common securities of 358,035,247. It also shows that the securities to be sold were originally acquired via restricted stock vesting as compensation from the issuer on 04/30/2020 (12,472 units), 03/19/2021 (4,039 units), and 05/12/2022 (16,228 units).
Precigen, Inc. became profitable as Papzimeos commercial sales scaled. For the quarter ended June 30, 2026, it generated total revenues of $54,978 and net income of $20,071 versus revenues of $856 and a net loss of $26,642 a year earlier (amounts in thousands). For the first six months, revenues were $78,230 with net income of $12,142, compared with $2,197 and a net loss of $80,795 in 2025.
Papzimeos contributed $53,070 of Q2 product revenue and $74,661 year‑to‑date, with Exemplar providing additional product and service revenues. Despite earnings, operating activities used $61,636 of cash in the first half, mainly from higher trade receivables and inventory. As of June 30, 2026, cash, cash equivalents and investments totaled $38,698 against long‑term debt of $93,880 under a term loan maturing in 2030.
Papzimeos, approved by the FDA in August 2025 for adult recurrent respiratory papillomatosis, now benefits from seven-year orphan drug exclusivity through August 14, 2032, and a Marketing Authorization Application is under EMA review, while the company continues advancing its AdenoVerse and UltraCAR‑T pipeline programs.
Precigen, Inc. reported a historic second quarter 2026, with total revenues of $55.0 million driven largely by PAPZIMEOS sales of $53.1 million for recurrent respiratory papillomatosis. The company generated net income of $20.1 million, or $0.06 per basic share, versus a $26.6 million loss a year earlier.
For the first six months of 2026, revenues reached $78.2 million and net income was $12.1 million, compared with an $80.8 million loss in the prior-year period, largely reflecting commercial PAPZIMEOS sales. R&D expenses declined due to capitalization of PAPZIMEOS manufacturing costs, while SG&A increased with launch-related spending. As of June 30, 2026, balance sheet figures (amounts in thousands) included cash and cash equivalents of $16,329, short-term investments of $21,879, long-term debt of $93,880, and shareholders' equity of $43,576, and management expects existing cash and PAPZIMEOS cash flows to fund operations through cash flow break-even by the end of 2026.
PRECIGEN, INC. Chief Operating Officer Rutul R. Shah exercised fully vested stock options to acquire 33,772 common shares at $2.33 per share and, on the same date, sold 33,772 shares at $6.50 per share under a Rule 10b5-1 trading plan. After the exercise, he held 123,304 stock options.
PGEN security holder Rutul Shah filed to sell common stock under Rule 144. The filing lists a proposed sale of 33,772 common shares through Fidelity Brokerage Services LLC on or after 08/03/2026 on NASDAQ, with an aggregate market value of $219,518.00 for the proposed sale.
The shares to be sold were acquired on 08/03/2026 by stock option exercise from the issuer for cash. The filing also reports a prior sale during the past three months of 42,924 common shares on 06/29/2026 for an aggregate value of $251,105.40.
PRECIGEN, INC. Chief Financial Officer Harry Thomasian Jr. sold 100,000 shares of common stock on July 31, 2026 at a weighted average price of $6.06 per share, with trades between $6.00 and $6.15, under a Rule 10b5-1 trading plan. After the sale, he directly holds 254,535 shares.
PGEN reporting person Harry Thomasian Jr. has notified plans to sell up to 100,000 shares of common stock through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of $605,609.66. The shares relate to restricted stock vesting on 08/28/2024.
In the past three months, reported sales include 28,571 shares for $165,196.70 on 06/29/2026 and 171,429 shares for $948,544.08 on 07/01/2026.